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CHAPTER 1 
 
BACKGROUND AND AIMS OF THE PROJECTS 
1.1 Background: paediatric Inflammatory Bowel Disease 
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD), Ulcerative colitis 
(UC) and IBD-unclassified (IBD-U) is a group of life-long chronic and relapsing 
inflammatory disorders of the gastrointestinal tract whose etiology has not been completely 
understood [1,2].  The most recent evidences involve a complex interaction between host 
genetic, environmental and microbial influences, resulting in a dysregulated mucosal 
immune response against the commensal intestinal microbiota [3,4].  The actual 
classification still distinguishes CD, characterized by the transmural, patchy inflammation 
with the potential involvement of all the gastrointestinal (GI) tract, from UC, mainly 
identified by the presence of continuous, superficial, mucosal inflammation, exclusively 
limited to the colon [5].  IBD-U describes all those patients with colonic disease but who 
otherwise have features that are not specific for CD or UC [5].  Nevertheless, it is now more 
evident that IBD encompasses a wide range of phenotypes with different responses to 
therapy and unpredictable natural history [6].  This concept is particularly pertinent to 
paediatric IBD, which has several specific considerations when compared with adult IBD 
[7].  These certainly include the relevant issues related to growth, development, pubertal 
maturation, bone health, and psychological impact on the patient and family, but also the 
unique features related to paediatric IBD phenotype, which is well-renowned to represent 
both a diagnostic and therapeutic challenge, being characterized by higher severity, 
including poor response to medical treatment, presence of extra-intestinal manifestations 
(EIM), and increased risk of surgery [8, 9].   
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1.2 Epidemiology: the burden of paediatric inflammatory bowel disease 
Although the incidence and prevalence of IBD differ among countries, the general 
trend clearly highlights an overall increase over the past few decades in western countries, 
especially in adolescence and young adulthood [10,11].  Indeed, approximately 25% of IBD 
has an onset in childhood with an incidence between 8 and 11 cases/100,000 
inhabitants/year and it is thought to rise more [12,13].  In a recent retrospective study 
conducted in Finland, during a 28-year observation period, the nationwide mean annual 
incidence of PIBD tripled from 7/100000 in 1987-1990 to 23/100000 in 2011-2014 [14].  
Considering that the current prevalence in USA has been estimated on about 100 to 200 
per 100 000 children, it is likely that most paediatricians will treat children with IBD in their 
practice [13, 15].  Moreover, although the major increase has been found within the age 
group of 10 to 12 years, it is also widely reported a higher number of cases in the sub-
cohort of Very Early Onset IBD (VEO-IBD), which includes children diagnosed before 6 
years of age [16].  These highly challenging cases, accounting for about 6 to 15% of all 
paediatric IBD, are characterized by a more aggressive phenotype and are thought to 
have a major genetic background [17,18].   
This radical change in the epidemiology of IBD, occurring during the last decades, 
has certainly exerted a profound impact on healthcare systems.  Indeed, a considerable 
proportion of IBD children will experience recurrent hospitalizations, aggressive medical 
treatments and complications leading to surgery, with a significant decrease of quality of 
life and burden of healthcare costs [19].  Already in 2008 Kappelman and colleagues 
assessed the direct costs of both adult and paediatric IBD [20].  The authors quantified 
that the mean annual costs for patients were $8265 for CD and $5066 for UC.  The total 
annual expenditure was estimated at $3.1 billion for CD and $2.1 billion for UC [20].  The 
costs were significantly higher for children younger than 20 years when compared with 
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adults [20].  As more recently reported the widespread use of biologics in the last decade 
should have further increased those estimates [21].   
1.3 Peculiarities in clinical presentation and diagnosis  
Paediatric IBD is characterized by a wide spectrum of clinical presentations, ranging 
from striking symptoms to more elusive signs [22, 23].  Besides the classical manifestations, 
which may include rectal bleeding, tenesmus, diarrhoea, abdominal pain, weight loss, 
fever, paediatricians should be aware of the importance of extra-intestinal symptoms, 
which may be subtle and even cause substantial diagnostic delays [24, 25].  Among the 
extra-intestinal symptoms, growth deficiency certainly represents the most important and 
undervalued IBD sign.  Indeed, a slowed height velocity may be the only manifestation for 
months, before the occurring of GI symptoms, particularly in children with CD [26].  Growth 
retardation has been reported up to 65% of CD children at diagnosis [27, 28].  It results from 
the combination of poor caloric intake, malabsorption and the direct effects of 
inflammation, causing growth hormone resistance [29].  It may be associated with the 
presence of significant pubertal delay, which itself represents a serious concern both for 
the psychological sequelae and for the follow-up of the patient [30].  In some cases, CD 
may manifest from the onset as a surgical emergency.  This is the case of complicated 
forms, such as stricturing and fistulising, which may be responsible of mechanic 
obstruction and even perforation [31].  All otherwise previously healthy children presenting 
with an acute intestinal surgical emergency, with an evidence of growth deficiency or other 
GI complaints may raise the IBD suspicion.   
In a greater percentage than adults, IBD children may present with the involvement 
of other organs, at the onset, before diagnosis or during the course of disease [32, 33].  EIM 
are usually more commonly associated with CD and the most frequently involved organs 
are joints, skin, liver, pancreas and eyes, with peripheral arthritis being the most prevalent 
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[32].  Among the others, pyoderma gangrenosum may be usually found during CD course, 
while sclerosing cholangitis is more often associated with UC [34, 35].  In a recent 
multicentre study conducted by the Swiss IBD cohort study group, EIM were detected 
before IBD diagnosis in 30% of the cases [36].  Within the most relevant findings, the 
authors confirmed that the prevalence resulted higher in paediatric than adult IBD patients 
and that IBD children with EIM were more likely to be treated with anti-TNF compared to 
those without, underlining the higher severity of the phenotype [36].   
Once the IBD suspicion has been raised, the diagnosis needs to be made with 
specific laboratory, endoscopic, histologic and radiological criteria, which have been 
recently revised by the ESPGHAN Porto group [37].  A baseline extensive laboratory 
evaluation, including complete blood cell count with differential, systemic inflammatory 
indexes, such as ESR and CRP, electrolytes and organ function tests is still recommended 
to orientate the diagnosis and screen the subjects needing endoscopic evaluation [37].  As 
it will be better analysed in the chapter 4, stool culture is considered mandatory before 
referring the children for endoscopy in order to rule out the differential diagnosis with the 
main GI pathogens [37].  Finally, testing for faecal calprotectin is strongly recommended 
due to its high negative predictive value.  Nevertheless, paediatricians should be aware of 
the potential false positives that are known to be higher in children than in adults, 
particularly in the age group<5 years [38].  The laboratory analyses need to be necessarily 
more extensive in the suspicion of an infantile IBD, defined as an age of onset<2 years.  
Indeed, in those specific cases the paediatric gastroenterologist has to rule out the 
differential diagnosis with a high number of primary immunodeficiencies [39].   
Endoscopy remains the corner stone in the diagnosis of paediatric IBD.  The 
ESPGHAN revised Porto criteria once more stressed the importance of performing both 
Upper GI endoscopy (UGIE) and ileo-colonoscopy at diagnosis, to increase the diagnostic 
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yield and allow a better discrimination between CD and UC [37].  The specific paediatric 
classification agreed in Paris in 2009 [40] and the revised Porto criteria [37] have further 
redefined the endoscopic pictures of paediatric IBD, well underlining the main differences 
with adult IBD.  Nevertheless, there is still the need of specific paediatric endoscopic and 
histologic scores, both for the diagnosis and the monitoring of disease.  In addition to the 
endoscopic procedures, the studies of the small bowel through the use of bowel 
ultrasound, magnetic resonance and, in specific cases, capsule endoscopy, have been 
continuously gaining importance during the last 10 years and are nowadays considered as 
indispensable in the first assessment of IBD in order to reduce the number of IBD-U [37].   
 
1.4 Therapeutic management: current and future perspectives 
The main goal of IBD therapeutic approach is to achieve and keep a long-term 
disease remission.  However, the concept of disease remission and more generally the 
goals of IBD therapy have dramatically changed during the last two decades and are still in 
continuous evolution [41, 42].  The introduction in 1998 of therapeutic monoclonal antibodies 
directed against TNFα (Infliximab, and successively Adalimumab), a major pro-
inflammatory pathogenic cytokine in CD and UC, has revolutionized the treatment of IBD, 
giving the possibility to switch from the non-specific conventional immunomodulatory drugs 
toward a pathway-based anti-inflammatory approach [43-45].  Following the same route, new 
biologics just came out and other will be soon available also for children, broadening the 
therapeutic possibilities [46].   
Due to the advent of such potent medications, the paediatric gastroenterologist, 
who has started treating his children only aiming for symptoms control, is now able to 
enlarge his horizon with several, pursuable goals.  The following should be nowadays 
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considered the main aims when deciding which therapeutic strategy starting in a child 
affected by IBD: 
• Induce and maintain clinical remission; 
• Induce mucosal healing; 
• Favour linear growth, weight gain and pubertal development; 
• Prevent disease complications; 
• Restore quality of life; 
• Minimize toxicity. 
In order to reach all the above-mentioned objectives, therapeutic strategies are evolving to 
look for the best approach able to change the natural history of disease [47, 48].  This 
process is particularly crucial in the paediatric IBD population, since as already underlined, 
young age at onset of disease is considered at high risk for poor prognosis, reinforcing the 
need for a highly effective treatment approach.  The initial management of most children 
with IBD includes the so-called conventional therapies, namely, corticosteroids (CCS), 5-
aminosalicylates (5-ASA), immunomodulators, such as Azathioprine (AZA) and 
Methotrexate (MTX), and nutritional therapy [49, 50].  The conventional approach, also 
known as “step-up” strategy, is based on the gradual escalation of drugs, from those with a 
better safety profile but a lower efficacy (5-ASA) to those with higher efficacy but an 
increased risk of adverse effects (including immunomodulatory and biologic agents).  The 
main advantage of “step-up” approach relies on reserving drugs with higher levels of 
toxicity only for those patients needing more intensive therapy [51, 52].  To date it has been 
the most used strategy in paediatrics, mainly due to its safety profile.  However, the “step-
up” approach is not able to alter to natural history of disease, reducing the disease 
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complications development and the need for surgery.  Therefore, the scientific community 
is gradually moving toward an early aggressive approach, the so-named “top down 
strategy” with the aim of modifying the natural history of the disease [53-55].  The “top-down” 
approach is basically characterized by the early use of biologics in those patients with a 
higher risk of poor disease outcomes [56].  This strategy comes from the evidences that 
biologics are able to induce mucosal healing (MH) in a significantly higher percentage of 
IBD patients when compared with conventional therapies [57-58].  Although the definition is 
not well standardized, MH mainly refers to the healing in a various degree of the 
endoscopic lesions [59].  The importance of achieving MH in clinical practice is related to 
the recent growing data that MH contributes to lower rates of clinical relapse, 
hospitalization and need for surgery, with a better health-related quality of life for patients 
[60-62].  Next to the MH, another emerging concept has been translated from rheumatology 
in the last years: the idea of reaching a “deep remission” [63-64].  With deep remission, the 
rheumatologists mean the alteration of the biological processes underlying synovial 
inflammation and progressive structural destruction, thereby preventing structural joint 
damage and functional decline [65].  Translated to the IBD, deep remission would be the 
achievement of a profound remission with the absence of clinical symptoms, no biological 
activity, complete MH, and at most disappearance of histological signs of inflammation [66-
68].  Therefore, the raising literature assessing the importance of MH and deep remission 
on disease outcomes is strongly pushing the adoption of “top-down strategies”, also in IBD 
children.  This process has also been facilitated by the widespread of biologics’ drug 
monitoring, the so-called “trough levels”, which has helped optimize medication dosing for 
individual patient, increase the rate of remission, and decrease the incidence of antibody 
formation resulting in loss of response [69-71].  Nevertheless, the scientific debate is still 
opened, due to the absence of well-defined risk stratification criteria from which a clinician 
can decide with a high degree of confidence, which patients will benefit from early anti-
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TNFα treatment [72, 73].  Indeed, the identification of patients at higher risk of poor disease 
outcomes represents the new paradigm of IBD research [74].   
 The last updated ESPGHAN guidelines on therapeutic management of paediatric 
CD tried to make the first steps in the risk stratification of CD children, identifying the 
following negative predictive factors: deep colonic ulcerations; persistent severe disease 
despite adequate induction therapy; pan-enteric disease; marked growth retardation; 
severe osteoporosis; penetrating and stricturing phenotypes; perianal disease [49].  A 
proper top-down strategy with anti-TNFαs has been strongly recommended only in case of 
active perianal disease in combination with appropriate surgical intervention and on an 
individualized basis in patients with severe growth retardation or other of the above-
mentioned negative prognostic factors [49].  Besides these cases, biologics are 
recommended only in children refractory to conventional therapy.  Hence, in most of the 
other children, it is still suggested a step-up approach, which we will briefly review.   
 One of the main changes respect to the past guidelines was to recognize as first-
line induction therapy, the exclusive enteral nutrition (EEN), in which 100% of total calories 
are delivered by commercial formulas and whole table foods are excluded from the diet for 
6-8 weeks [49].  Indeed, EEN, besides showing the same efficacy of CCS in inducing 
clinical remission, is able to achieve MH, has a better impact on nutritional issues and has 
no side effects [75-77].  CCS should be used only in those children not compliant or not 
responding to EEN [49].  For the maintenance of remission, the conventional 
immunosuppressants, including AZA or MTX, are still considered as valid options, due to 
their demonstrated efficacy [49].  Only in patients with mild colonic inflammation, 5-ASA 
may be used [49].  Although strongly limited by the advent of biologics, surgical intervention 
is still necessary in limited cases, such as active involvement of short segments, and the 
treatment of complications (fistulising or stricturing phenotypes) [78].   
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With regards to UC, based on the most recent guidelines, which are currently being 
updated, the therapeutic management mainly differs from CD for the absence of a 
nutritional therapy [50].  Indeed, the only available induction therapy is represented by CCS, 
which are still recommended in all moderate to severe UC children [50].  Due to the more 
superficial inflammation, 5-ASA are still considered very good options in many UC children 
and they are recommended as induction therapy in mild cases and as first maintenance 
therapy in mild to moderate patients.  AZA is still the most used medication in UC in 
Europe and it is recommended at diagnosis in severe cases or otherwise in case of early 
relapse or intolerance to 5-ASA [50].  MTX may be used as a second-line 
immunosuppressant, although there is no evidence of efficacy reported in literature [50].   
Anti-TNFαs have been demonstrated their efficacy also in children with UC and are 
recommended in all those patients refractory to conventional therapy [50].  Differently from 
CD, surgery is potentially curative in UC and keeps its role in those children refractory to 
medical treatment.  The indicated intervention is the sub-total colectomy with the 
subsequent ileo-anal-pouch collection.  This issue will be better addressed in Chapter 6.   
Nevertheless, both CD and UC therapeutic algorithms will soon need to be updated 
due to the advent of new biologics.  Particularly, two new molecules including, 
Vedolizumab, a humanized anti-a4b7 integrin, IgG1 monoclonal antibody, and 
Ustekinumab, fully human anti-p40 IgG1, have already being used off-label in IBD children 
refractory to anti- TNFαs, with moderate efficacy [79-82].   
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1.5 Aims  
Given these premises, the aims of this thesis project are: 
 
• To provide new insights in paediatric IBD pathogenesis, including the influence of 
environmental factors;  
• To characterize the phenotype and the disease course of IBD in paediatric age;  
• To improve the knowledge on the relationship between Gastrointestinal Infections, 
including Clostridium difficile (C. difficile) and Yersinia enterocolitica, and paediatric 
IBD, both for differential diagnosis and relapse management;  
• To describe the prevalence, the natural history and the management of extra-
intestinal manifestations, including IBD related anaemia and pancreatic 
involvement;  
• To improve the current therapeutic strategies for the management of paediatric IBD.   
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CHAPTER 2 
NEW INSIGHTS IN PAEDIATRIC IBD PATHOGENESIS 
 In the last decade, significant progress has been made in unravelling the 
pathogenesis of IBD.  It is now quite clear that 3 major players have a role in the process 
of IBD development: the genetics, the intestinal microbiome and the environment [83].  
During this chapter, we will review this topic, and particularly the impact of environmental 
factors, reporting the results of the paper “Impact of Environmental and Familial 
Factors in a cohort of pediatric patients with Inflammatory Bowel Disease” recently 
published in the Journal of Pediatric Gastroenterology and Nutrition (J Pediatr 
Gastroenterol Nutr. 2017; 64:569-574).   
 
2.1 The impact of environmental factors  
Due to the early onset age, genetics has always been thought to play an important 
role in the paediatric IBD development and in some cases of VEO-IBD is certainly the 
preeminent factor [16, 39].  Technological advances in DNA analysis and sequencing, 
together with the use of huge multinational databases, allowed the achievement of 
numerous genome-wide association studies (GWAS) both in adults and children and the 
identification of more than 200 IBD risk-associated loci [84-86].  Many of them are strictly 
linked with immune-mediated pathways, including autophagy, cell-mediated immune 
responses and innate immune responses.  These findings led to the hypothesis that the 
dysregulation of at least some of these mechanisms may interplay with intestinal 
microbiome, inducing and perpetuating the intestinal inflammation [4].  The importance of 
microbiome has been renowned since the publication in the early 90s of studies 
demonstrating that in animal models of colitis the absence of intestinal bacteria did not 
allow the development of colonic inflammation [87].  More recently, the development of next 
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generation sequencing technologies has deeply elucidated microbiome alterations in IBD 
patients.  A variety of associated changes in microbiota community composition have been 
revealed, including: reduced diversity, decreases in the relative abundance of certain 
groups, such as Firmicutes and Bacteroidetes; increases in the contribution of 
Proteobacteria and Actinobacteria and reductions in specific species, such as 
Faecalibacterium prausnitzii [87, 88].  More recently, a large multicentre North-American 
cohort confirmed that microbiome alterations may be found already at diagnosis in CD 
naive-treatment children [89].   
However, both the advances of genetic and microbial evidences, instead of 
reducing the role of environmental factors, have paradoxically reinforced their importance 
[90].  This is mainly due to a series of clues.  First, genetics is only able to explain 
approximately 25% of the heritability of IBD, as confirmed by the incomplete penetrance of 
monozygotic twins [84].  As a matter of fact, all the identified polymorphisms, individually, 
only give a modest increase of the IBD risk [84].  The second fact that favours the 
environment influence is certainly represented by the remarkable and fast changes in IBD 
epidemiology.  As well pointed out in Chapter 1, over the last 50 years a striking increase 
of the incidence has been observed both in adults and children, and it is still in progress 
[91].  These findings certainly cannot be explained by the genetics, considering that 
changes in genetic predisposition factors usually needs centuries.  Finally, the geographic 
distribution of disease, mostly concentrated among the developed countries, has always 
blamed westernized lifestyle, and above all the diet [92].  This has been further confirmed 
by the migration studies, which demonstrated that people moving from low IBD incidence 
areas to high IBD incidence regions tend to acquire the risk of the host country [93, 94].   
Taken together all these observations strongly suggest that environmental factors are 
playing a critical role in the development of these disorders and in the modulation of 
disease phenotypes over time.   
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Many researchers are now referring to the environmental factors as to the 
“exposome”, a term that encompasses the composite of accumulated environmental 
exposures, starting in utero and continuing through childhood and into adulthood [95].  This 
aggregate “exposome” is probably able to affect the likelihood of developing IBD, 
interacting trough microbial and epigenetics modifications [95].  Thus, there is a growing 
interest in identifying the different factors within the exposome, not only to better 
understand the process behind IBD development, but most of all to generate dietary, 
lifestyle, and pharmacologic preventive interventions that will enable us to reduce the 
incidence and to improve the clinical course of our patients.  So far, only tobacco smoking 
and appendectomy have been demonstrated to be strongly associated with IBD incidence 
[96-98].  In addition, many papers supported the so called “hygiene hypothesis”, which 
correlates the epidemiological rise in IBD incidence over the 20th century, with the 
improvement in general hygienic conditions (i.e. free access to clean water, smaller family 
size, higher use of antibiotics, etc.) [99-100].  Many evidences suggest that dietary factors are 
crucial in IBD pathogenesis [101, 102].  To date we know that exposure to diets rich in the 
saturated fatty acids found in red meat appears to place individuals at increased risk, while 
an increased dietary fiber intake appears to be inversely related to the risk of developing 
IBD [103-105].  Moreover, some evidences in mice suggests that dietary emulsifiers, the 
common food additives used to facilitate the dispersion of oil into water, promote the 
generation of a pro-inflammatory microbiome signature and predispose to intestinal 
inflammation [106, 107].  
Given these premises and considering this as a “hot topic” in IBD research field, we 
decided to perform a retrospective analysis of our paediatric IBD population with the 
purpose to investigate the relation between the exposure to some of the main 
environmental factors and the risk of developing UC and CD.  In addition, we evaluated 
the adherence to Mediterranean diet through the administration of a validated 
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questionnaire, the KIDMED [108].  We hypothesized, indeed, that the Mediterranean diet, 
characterized by elevated intakes of fruits and vegetables, olive oil, bread, and cereals 
may exert a protective role in the development of IBD.  We compared 264 IBD children 
with 203 healthy controls recruited in public schools and in the outpatients’ clinic.  Children 
and parents answered a multi-items questionnaire covering a wide range of possible 
environmental factors associated with IBD development from the birth to the date of 
diagnosis.   
The results of the study confirmed the influence of environmental factors as 
possible explanation for the significant increase of IBD incidence.  Indeed, we identified 
numerous risk as well as protective factors.  Above all, the striking difference in 
Mediterranean diet adherence, between cases and controls, has to be considered the 
most innovative finding of our study.  Indeed, the Mediterranean diet is perhaps 
considered one of the healthiest dietary models currently existing.  Numerous 
epidemiological and experimental nutrition studies have demonstrated how Mediterranean 
countries benefit from lower rates of chronic disease morbidity and higher life expectancy 
[109, 110].  To the best of our knowledge this is the first paediatric study reporting the 
hypothesis that Mediterranean diet may have a protective effect for IBD development.  If 
our data will be confirmed by further studies, we may have found a new possible dietary 
strategy for prevention and eventually treatment of our patients.   
Among the other findings we confirmed many of the factors related to the Hygiene 
Hypothesis.  Indeed, we demonstrated that owning pets, having a reduced number of 
toilets at home and a higher number of siblings were associated with a lower risk for both 
CD and UC.  Family size can be used to indicate the level of overcrowding in a home, 
which has been associated with potential exposure to infection [111].  The same concept is 
related to the number of siblings.  Indeed, siblings may influence the development of IBD 
altering exposure patterns to microorganisms in early life, affecting acute manifestation of 
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infections, or influencing age of transmission and severity [112].  As a further demonstration, 
the control group showed a higher number of familial H. Pylori infection and parasitosis.  
Looking at the risk factors, as previously described, we reported a higher exposure to the 
antibiotics in CD children.  The use of antibiotics may alter the composition of the gut 
microbiome with the loss of potentially beneficial bacteria and the emergence of potentially 
pathogenic bacteria [113, 114].  Alternatively, the loss of immune interaction with potentially 
pathogenic bacteria at an early age fails to prime the immune system to harmful organisms 
that it may encounter later in life [113, 114].   
We concluded that environmental factors exert a fundamental role in IBD 
development.  Future studies will need to address the molecular mechanisms underlying 
the interactions between exposome, genetics and microbiome in order to increase our 
comprehension of pathogenetic mechanisms and design new possible preventive and 
therapeutic interventions.   
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CHAPTER 3 
 
CHARACTERIZATION OF PAEDIATRIC IBD PHENOTYPE 
 
  As partially underlined during Chapter 1, childhood-onset IBD is considered a 
different phenotype from adult-onset or elderly-onset disease with many peculiarities in its 
phenotypic expressions and generally a more aggressive disease course [115].  Within this 
chapter we will describe both paediatric CD and UC phenotypes reporting the results of 2 
different papers.  The first “Autophagy genes variants and paediatric Crohn’s disease 
phenotype: a single-centre experience” has been published in Digestive and Liver 
Disease (Dig Liver Dis. 2014; 46:512-7); the second “The changing face of paediatric 
ulcerative colitis: a population-based cohort study” has been recently submitted and it 
is currently under review.   
 
3.1 Impaired autophagy and paediatric Crohn’s disease (CD) phenotype   
The severity of paediatric CD is known since the first population-based studies 
published in the early 2000 [31, 115] and it has been confirmed by further papers [116, 117].   
Compared to adults, the main characteristics of paediatric CD are: a more extensive 
anatomic involvement, including a higher frequency of pan-enteric disease and a major 
involvement of colon; an inflammatory behaviour at diagnosis with an early disease-
progression toward complicated forms, including both stricturing and fistulising disease; an 
early need for immunomodulation and a higher risk for surgery [31, 115-118].  Therefore, in the 
last 10 years an effort has been made in order to characterize possible clinical, laboratory, 
microbial and genetics biomarkers able to differentiate children with a higher risk of poor 
disease outcomes [74, 119, 120].  In this paragraph, we will analyse the role of genetic factors 
in predicting CD disease phenotype.  
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The understanding of the genetic basis of CD started in 1996, with the discovery of 
NOD2/CARD15, the first identified gene, and probably one of the first successes in the 
genetics of complex polygenic diseases [121].  As underlined in chapter 2, GWAS have 
given evidence for several determinants, including genes encoding ATG16L1 (autophagy-
related 16-like 1) and IRGM1 (immunity-related GTPase family M) [122].  All these genes 
are involved in a biological process known as autophagy, which plays a role in protein 
degradation, antigen processing, regulation of cell signalling, and many other pathways 
essential to the regulation of inflammation [123].  Some studies tried to correlate the 
presence of the above-mentioned polymorphisms with CD phenotype, both in adults and 
children.  In details, 2 different papers found a strong association between NOD/CARD15 
SNPs and major ileal or ileo-colonic localization of CD in children [124-125].  With regards to 
ATG16L1, a correlation between ATG16L1 risk allele and a more frequent ileal 
involvement of CD has been described in adults, but there are no evidences in children 
[126].  In addition, only one paediatric study analysed the recurrence of IRGM1 SPNs and 
CD risk, but no associations were found between these SPNs and the clinical course of 
the disease [127].   
Considering this background literature, the aims of our study, carried out in our 
cohort population in 2014, was to evaluate the relationship between the main risk alleles of 
NOD2/CARD15 (rs2066844; rs2066845; rs2066847), ATG16L1 (rs2241880) and IRGM1 
(rs13361189; rs4958847), and the corresponding clinical phenotype.  In particular, we 
wanted to ascertain if patients carrying the above-mentioned alleles showed a more 
aggressive phenotype.  Hence, we retrospectively analysed the clinical course of our 
cohort of CD children diagnosed from 2001 to 2013.  All the children were genotyped for 
all the above-reported risk alleles.   
Our data clearly underlined that patients carrying the homozygous risk allele 
rs2241880 of ATG16L1 had a significant trend to switch from an inflammatory to a 
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stricturing behaviour during the course of disease.  In line with this finding, ATG16L1 risk 
allele was also associated with the absence of perianal disease, confirming that the 
expression of this genetic determinant is specifically linked with the development of 
stricturing and fibrosis rather than fistulising phenotype.  To our knowledge, this is the first 
paediatric study reporting an association between the presence of rs2241880 risk 
polymorphism of ATG16L1 in children with CD and a more severe phenotype of disease.   
To support the hypothesis of a worst phenotype in homozygous patients, we found that 
rs2241880 risk polymorphism was related to a major incidence of clinical relapses and with 
the earlier introduction of immunosuppressants.  In addition, children carrying rs2241880 
risk allele show higher values of faecal calprotectin and CRP at diagnosis compared with 
patients carrying ATG16L1 heterozygous or wild type variants.  Indeed, although the role 
of faecal and serologic markers in predicting IBD disease course is still controversial, the 
hypothesis that higher values at diagnosis could predict a more severe disease course has 
been claimed [128].   
Differently from ATG16L1, several studies tried to identify the role of 
NOD2/CARD15 variant alleles in determining clinical phenotype in both adults and 
children.  The most recurrent finding of this literature is that children and adolescents 
carrying NOD2/CARD15 have a more frequent small bowel involvement, and more 
precisely, the disease tends to be localized in terminal ileum [129, 130].  In agreement with 
these evidences, our analyses of genotype-phenotype correlation showed that patients 
carrying the NOD2/CARD15 rs2066847 (1007fs) heterozygous allele had a more frequent 
ileal involvement than children showing the wild type variant for the same SNP.   
We also investigated whether IRGM1 gene, recently identified to play a role in the 
development of CD and also shown to be involved in autophagy, may have a role in 
predicting CD phenotype.  In contrast, to the extensive amount of work that has been 
accomplished in identifying and characterizing the complex network of ATG molecular 
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mechanisms, there is much less known about the role of the IRGM1 related autophagic 
pathways.   At the univariate analysis, we found that the presence of IRGM1 rs13361189 
variant allele was associated with a lower use of immunosuppressant therapy, highlighting 
a possible role on the development of a milder phenotype.  However, this association was 
not confirmed at the multivariate logistic regression analysis.  Therefore, we weren’t able 
to find a genotype-phenotype correlation for IRGM1 and other studies are needed to 
elucidate its role in CD pathogenesis.   
In conclusion, the findings of this work confirmed that genetic susceptibility might 
have an important role in the etiology of paediatric-onset IBD and in the determination of 
CD phenotype.  In our paediatric cohort, ATG16L homozygous risk allele seemed to be a 
key player in determining stricturing complications.  In addition, we confirmed that NOD2-
CARD15 is associated with ileal involvement.  These data stress once more the 
importance of genetic susceptibility research in larger paediatric onset IBD cohorts in order 
to find new genes and possibly allow an early treatment stratification of these patients.   
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3.2 Phenotype and clinical course of paediatric Ulcerative Colitis  
 The onset of UC in paediatric age is today considered both a diagnostic and a 
therapeutic challenge, when compared with adults [8, 115, 131].  From the diagnostic 
perspective, adults’ UC has a quite clear and recognizable pattern, mainly characterized 
by a typical superficial, chronic mucosal inflammation, which involves the colon starting 
from the rectum and proceeding continuously towards proximal segments.  Differently, 
paediatric UC may be characterized by the presence of atypical phenotypes, which are 
responsible of many IBD-U and even wrong CD diagnosis.  The revised Porto criteria, 
published in 2014, tried to identify and classify all of them, with the aim of improving the 
quality of diagnosis in children [37].  Six different atypical UC phenotypes have been 
identified:  
1) Rectal sparing: absence of macroscopic disease in rectum or recto-sigmoid; 
2) Short duration of disease variant: patchy disease in biopsies or lack of typical 
architectural distortion in pathological specimens; 
3) Cecal patch:  left-side colitis plus an area of inflammation in cecal region; 
4) Upper gastrointestinal involvement (UGI): presence of gastric erosions and non-
serpiginous small ulcers; 
5)  Acute severe colitis (ASC):  disease contiguous from the rectum and trans-mural 
inflammation with deep ulcers; 
6) Backwash ileitis: macroscopic, short segment, non-stricturing terminal ileitis, without 
granulomata. 
 
To date the incidence of atypical features has been poorly described. In addition, all the 
papers, addressing this issue, have been published before the Porto classification, 
therefore identifying some, but not all the phenotypes.  This is the case of Eurokids data 
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registry, published in 2013, which reported only the incidence of UGI, rectal sparing and 
backwash ileitis [132].   
From a therapeutic perspective, it is well known that childhood-onset UC is 
characterized by a more extensive colonic involvement and a more rapid severe course 
when compared to adult UC, including a higher risk of corticosteroids dependency, an 
earlier immunosuppressive therapy introduction and surgery occurrence [115, 131].  Already 
in 2008, Van Limbergen and colleagues comparing a cohort of children with UC with an 
adult population demonstrated that 74.5% of paediatric patients were diagnosed with an 
extensive colitis based on the Montreal classification [115].  These findings were confirmed 
by the data from EPIMAD registry.  As a matter of fact, Gower Rosseau et al found that 
paediatric UC is characterized by widespread localization, a high rate of disease extension 
and a colectomy rate of 20% after 5 years of follow-up [131].   
Although this could seem a huge amount of data, as well underlined in a recent 
systematic review, most of the studies have been conducted in the pre-biologics era, 
before the widespread use of immunosuppressants and biological therapies [133].  
Considering the need to identify therapeutic strategies able to modify the course of 
disease, it is worth to re-evaluate the natural history of paediatric UC in the last decade to 
understand if the earlier introduction these more effective drug exerted an effect on the 
natural history of paediatric UC.   
 Therefore, the aims, of our paper were to describe UC phenotype at diagnosis, also 
looking at the prevalence of atypical features, and to characterize the natural history of 
disease in our large cohort of UC patients.  We performed a paper chart review of children 
and adolescents diagnosed with UC between 2 and 18 years from January 2007 to 
January 2016 and we finally included in the analysis 111 children.   
Among the most innovative findings of our paper, we firstly reported the prevalence 
of all the atypical phenotypes at diagnosis, based on the recent Porto classification.  We 
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demonstrated that the overall prevalence of atypical phenotypes at diagnosis in paediatric 
UC is rather high, reaching the 49.5% of our cohort, thus confirming the risk of 
misdiagnosis.  The most recurrent phenotype resulted UGI, with a frequency of 20.5%, 
while patchy histologic inflammation, or short disease duration, was the second most 
frequent atypical feature.  Not surprisingly, we found a higher prevalence of ASC among 
the early-onset IBD group (age<6 years), once more underlining severe clinical course of 
this specific group-age.  More generally, the whole paediatric UC confirmed its major 
severity respect to the adult UC.  Indeed, the phenotype of UC in our cohort is well 
synthetized by the high percentage of pancolitis/extensive colitis at diagnosis (60%), the 
disease extension during the course of disease (30%) and the early relapse rate (47.7%).  
We were also able to provide useful insights regarding possible early predictors of a worst 
outcome of disease.  Many recent papers assessed the value of PUCAI at diagnosis and 
at 3 months, as the best predictor of sustained steroid free remission, ASC and early need 
for rescue therapy [134-136].  In our cohort, children with an early relapse within the 6th 
month showed higher values of PUCAI, CRP and faecal calprotectin at diagnosis, which 
may therefore be used as potential markers to orientate the initial treatment strategies.   
Looking at therapeutic strategies, up to 54% of our patients needed to start AZA 
and very early during the course of disease, with a median time of 7 months.  At the 
maximal follow-up about 8.1% started infliximab.  These data confirm that we tend to use 
more immunosuppressive and biologic drugs and that we use them earlier during the 
course of disease.  Although this aggressive strategy is certainly reflective of the 
phenotype severity, our findings suggest at least a partial efficacy on the clinical course.  
Indeed, we reported a surgery rate at 5 and 10 years of 8 and 16%, respectively, which is 
significantly lower when compared with the early publications and it is in line with the more 
recent papers.  As a matter of fact, looking at the literature we can observe a progressive 
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decrease of surgery rate, starting from the 26.1% at 5 years reported from Van Limbergen 
and colleagues in 2008 [115] and arriving to the more recent 8% reported by Malmborg et 
al. and confirmed by our results [137].  Although it is still unclear whether surgery is merely 
postponed, immunosuppressive and biologics may have modified the disease course.   
In conclusion, we confirmed that paediatric UC represent both a diagnostic and a 
therapeutic challenge, for the high percentage of atypical features and for the severe 
clinical course.  Nevertheless, the decreased surgery rate observed in the last decade may 
suggest that an early aggressive approach may be able to modify the natural history of 
disease.   
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CHAPTER 4 
 
GASTROINTESTINAL INFECTIONS AND PAEDIATRIC IBD 
  The management of GI infections in paediatric IBD is still considered a hot topic, 
being crucial both at the disease onset and during the follow up for differential diagnosis 
and therapeutic issues [138].  Furthermore, it is still unclear whether or not GI infection may 
trigger the disease and act as a player in IBD pathogenesis [139].   
As a matter fact within the revised Porto criteria for IBD diagnosis [37], the following 
concepts are mainly stressed:  
• In children with suspected IBD, enteric infections should be excluded as cause of 
the symptoms preferentially before endoscopy is performed; 
• The search for bacterial infections should include a stool culture to exclude 
Salmonella, Shigella, Yersinia, Campylobacter, and C. difficile toxins in all of the 
children. Screening for enteric viruses is rarely helpful, while testing for Giardia 
lamblia is recommended in high-risk populations or endemic areas; 
• The identification of a pathogen does not necessarily exclude a diagnosis of IBD, 
since a first episode or flare of IBD may be triggered by a documented enteric 
infection. 
The last point is mainly correlated to the concrete risk of a delayed diagnosis [37].   
We will revise this topic within this chapter through the description of the paper 
“Clostridium difficile and pediatric Inflammatory Bowel Disease: a prospective, 
comparative, multicenter, ESPGHAN study” published in Inflammatory Bowel Disease 
(Inflamm Bowel Dis. 2014; 20:2219-25) and the letter to the editor “Yersinia 
Enterocolitica Ileitis Mimicking Pediatric Crohn's Disease” also recently published in 
Inflammatory Bowel Disease (Inflamm Bowel Dis. 2017; 23: E15-E16). 
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4.1 The relationship between Clostridium difficile infection and paediatric IBD 
 C difficile is a gram-positive, spore-forming obligate anaerobe that causes a 
spectrum of clinical presentations.  Symptoms of C difficile infection can range from mild, 
self-limited diarrhoea to severe colitis with cramping, haematochezia, pseudo-membrane 
formation, and intestinal perforation [140].  Despite considerable advances in understanding 
the epidemiology, immunology, and pathogenesis, C. difficile is still the most frequent 
cause of nosocomial bacterial infectious diarrhoea in developed countries and it has grown 
in frequency and severity over the three decades.  In the last 10 years the epidemiology of 
C. difficile infection has profoundly changed.  Next to the classical risk groups, including 
patients treated with broad-spectrum antibiotics, hospitalization, oncologic and severely 
immunocompromised children, new factors favouring the infection came out [140].  Among 
those, being affected by IBD has been widely reported to increase the risk of C. difficile 
infection both in adults and children [139, 141-147].  However, the prevalence of C. difficile 
infection among children with IBD is still unclear due to the variable data reported, ranging 
from 3.5% to 69% [139, 146-150].  The increased risk of infection is not believed to be due to 
the frequent use of immunosuppressive agents and hospital based-services, but also to 
IBD itself [151].   
The management of C. difficile during the IBD natural history encompasses different 
phases, being associated with IBD in several ways, including triggering disease flares, 
sustaining activity, and in some cases, acting as an “innocent” bystander.  This usually 
makes things complicated for the clinician.  Indeed, when a flaring IBD patient is found to 
be infected with C. difficile, the therapeutic dilemma is whether to withhold 
immunosuppression or alternatively to administer antibiotics along with intensified 
immunosuppressant therapy to treat a possible concurrent IBD exacerbation [152].   
Furthermore, some reports also underlined that IBD course may substantially deteriorate, 
after C. difficile infection [153, 154].  In order to answer some of these questions and to collect 
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a higher number of cases, we performed a prospective, multicentre study, involving 8 
different ESPGHAN centres.   
The primary aim of this study was to investigate the occurrence of C. difficile 
infection in paediatric patients with IBD and to compare with a group of children affected 
by another GI pathology, such as celiac disease; the secondary aim of the study was to 
evaluate the natural history and the disease course of C. difficile infected IBD children.   
Between October 2010 and October 2011, the study group enrolled 211 children affected 
by IBD and 112 celiac children.  All the children were tested for the presence of C. difficile 
toxins A and B in their stools.  IBD group had a further stool collection after 6 and 12 
months from the enrolment.   
  Examining the results, we were able to observe a whole epidemiologic picture of C. 
difficile infection in IBD children in Europe and Israel.  The occurrence of C. difficile at the 
enrolment in the IBD group was 7.5%, while the overall 1-year occurrence, considering 
patients completing the follow-up, was 20.1%.  As expected the occurrence in IBD was 
significantly higher than celiac children (0.8%).  We decided to test patients with celiac 
disease as control group, to verify whether another gastrointestinal pathology, with 
described microbiota alterations [155], may confer a higher susceptibility to C. difficile 
infection.  This finding confirms that the increased risk is specifically related to the IBD.  As 
a further validation of this hypothesis, the classical C. difficile risk factors, including 
antibiotic therapy, immunomodulators and hospitalization did not result to be associated 
with the infection.  On the contrary, the infection seemed to be more community acquired.  
Among the risk factors IBD related, in agreement with the literature, we found that the 
colonic involvement was highly prevalent in children with C. difficile and that there is no 
specific type of IBD predisposing to the infection [156].   
 Not surprisingly we found a huge variation of C. difficile infected patients among the 
different countries, ranging from 0 to 24.1%.  Despite these variations, we assisted to all 
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the possible C. difficile clinical manifestations.  C. difficile was diagnosed in a high 
percentage of cases at disease onset, as previously described by Kelsen et al [147].  This 
result underlines the possibility of a diagnostic delay and once more addresses the 
question of a possible role of C. difficile as disease trigger.  During the follow up, C. difficile 
was significantly associated with an active disease, confirming the relevance of testing it 
during IBD flares.  On the other side of the coin, we also reported a non-negligible number 
of cases showing an asymptomatic carriage of C. difficile.  The significance of 
asymptomatic finding of C. difficile toxins in the stools and the risk of a subsequent relapse 
is still unclear in literature [157].  Nevertheless, our study may provide useful insights.  
Indeed, to our knowledge this represents the first prospective multicentre study, 
addressing the follow-up of C. difficile infected IBD children.  We found that C. difficile–
positive patients at the enrolment, including those with an asymptomatic carriage, showed 
a substantial risk for exacerbated disease course, as demonstrated by the need for 
immunosuppressant escalation, the higher frequency of active disease, the increased 
colectomy rate, and the higher number of hospitalization at 6 months.  Differently from 
previous studies [146], we found a high success rate of C. difficile eradication (86.6%) after 
treatment.  Nevertheless, as reported above, in most of the cases, the eradication of the 
infection did not prevent a subsequent complicated IBD course, suggesting that C. difficile 
may act more as a relapse trigger rather than a “leading actor” of the symptoms.  Another 
possibility is that C. difficile detection may be an expression of significant dysbiosis, and 
therefore, it may be interpreted as an indicator of severe disease course.   
  In conclusion, our results show the whole picture of the vexed relationship between 
C. difficile and IBD.  Paediatric IBD confers a specific risk of C. difficile infection, probably 
linked to its dysbiosis.  C. difficile positive toxins may be encountered at onset of disease, 
during the IBD course, in both symptomatic and asymptomatic patients.  It is therefore 
worth testing in any case, since it seems that C. difficile detection may complicate the 
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natural history of disease or it may simply represent the microbial signature of a worst 
outcome. 
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4.2 Differential diagnosis between Yersinia enterocolitica ileitis and CD  
 Yersiniosis is the third most commonly reported bacterial zoonoses in humans and 
it is a frequently reported gastrointestinal disease in Europe, especially in infants and 
young children [158].  The consumption of contaminated food, milk or water is the route of 
transmission of yersiniosis.  Yersinia Enterocolitica is the most frequent Yersinia species 
accountable for human cases [158].  Yersinia infection is most commonly detected in 0-4-
year-old children.  Clinical presentation is variable from mild enteric symptoms to severe 
case with fever and bloody diarrhoea and complicated by extra-intestinal involvement [159].  
An age-dependent symptomatology has been described.  Indeed, in younger children the 
infection leads to an enterocolitis characterized by fever, vomiting and diarrhoea, while 
infants <3 months have an increased risk of extra-intestinal manifestations, including 
bacteraemia and metastatic infections, such as liver and spleen abscesses, pneumonia, 
septic arthritis, meningitis and endocarditis [160, 161].  In older children, abdominal pain, 
mainly localized in the lower right quadrant, is the most common symptom and usually 
represents the clinical expression of terminal ileitis and mesenteric lymphadenitis [160, 161].  
A small percentage of patients may develop a chronic active ileitis and/or colitis, with 
persistent abdominal pain and/or diarrhoea, clinically mimicking IBD.  Indeed, Yersinia 
Enterocolitica enteritis strongly resembles the major aspects of CD [162, 163].  Abdominal 
ultrasound examination is indistinguishable, showing thickening of terminal ileum wall and 
enlarged mesenteric lymph nodes, while colonoscopy is usually characterized by round or 
oval elevation and ulcers at the terminal ileum.  Finally, Yersinia species may also 
histologically mimic Crohn’s disease causing epithelioid granulomas with lymphoid cuffing, 
transmural inflammation with lymphoid aggregates, mucosal ulceration and cryptitis [164].   
 Here, we reported the case of an 11-year-old boy referred to our unit for a 4-month 
history of recurrent abdominal pain (RAP).  At the onset of symptoms, the patient 
presented abdominal pain associated with diarrhoea, which disappeared few days later.  
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Successively, RAP was invariably associated with nausea and loss of appetite.  Our 
laboratory investigations, including a complete and a differential blood count, organs 
function markers and acute phase reactants were normal.  Faecal calprotectin was 185 
ug/g.  Celiac disease antibodies, anti-tissue transglutaminase and anti-endomysium, 
resulted negative.  Our orientation was for a functional GI disorder, but an ultrasound 
exam of the abdomen revealed thickness (3.8 mm), loss of stratification and increased 
vascularization of terminal ileum wall, associated with enlarged mesenteric lymph nodes, 
with a suspicion of CD.  Thus, we decided to perform an ileo-colonoscopy.  The exam 
revealed the presence of aphthous ulcers and granularities at the terminal ileum.  These 
findings were consistent with a diagnosis of CD, A1b-L1-B1-G0 on the basis of Paris 
Classification [40].  Histology was confirmative, revealing active terminal ileitis with chronic 
inflammation at the lamina propria, cryptitis, and superficial erosion.  Therefore, EEN was 
started, with poor results on the abdominal pain.  Eight days after EEN’s beginning, stool 
cultures revealed positivity for Yersinia enterocolitica.  EEN was discontinued and 
trimethoprim/sulfamethoxazole was started for a 10-day course with a prompt clinical 
improvement.  At the 1-month follow-up, the patient referred no episode of abdominal pain.  
A magnetic resonance enterography demonstrated the absence of small bowel mural 
thickening, no increased vascularization and disappearance of the previous 
lymphadenopathy.   
 This case once more suggests the importance of an extensive infectious diagnostic 
evaluation in the suspicion of paediatric IBD.  As specified within this chapter, the 
ESPGHAN revised Porto criteria clearly state that in all children with suspected IBD, 
enteric infections should be excluded as cause of the symptoms, preferentially before 
endoscopy [37].  Yersiniosis is included within the stool culture panel to be performed [37].  
Unfortunately, this is not always feasible taking into account the time necessary to achieve 
all microbiological cultures.  In addition, most clinical microbiology laboratories do not 
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routinely use selective techniques to isolate Yersinia on stool cultures unless specified.  To 
complicate this scenario, the identification of a pathogen does not necessarily exclude a 
diagnosis of IBD because a first episode of IBD may be triggered by a documented enteric 
infection.  As a matter of fact, it has been reported that paediatric patients with a diagnosis 
of CD showed a significant higher presence of Yersinia DNA in colonic specimens when 
compared with controls [165].  Indeed, as indicated, a clinical longitudinal follow-up of these 
patients may be recommended [37].  In our case, the lack of response to EEN and the 
immediate resolution of both symptoms and radiologic signs of inflammation, after 
antibiotic therapy, should have definitely rule out the diagnosis of IBD.   
  In conclusion, this case demonstrates the clinical, sonographic and endoscopic 
similarities between Yersinia enterocolitica ileitis and CD.  Thus, in the diagnostic work-up 
of suspected paediatric IBD, it is mandatory to exclude yersiniosis, requesting specific 
stool cultures.  In any case, these patients may benefit of a clinical follow-up to definitely 
exclude an IBD diagnosis.   
 
 
 
    
77	
	
	
 
    
78	
	
	
    
79	
	
	
CHAPTER 5 
MANAGEMENT OF EXTRA-INTESTINAL MANIFESTATIONS 
 As previously underlined in chapter 1, one of the peculiarities of paediatric IBD is 
the higher percentage of EIM [32, 33].  Their management is usually problematic due to the 
absence of specific treatments and the need to find a common therapeutic strategy both 
for the intestinal and extra-intestinal disease [34].  In some cases, particularly when it is 
involved the muscle-skeletal system, patients will need a quick escalation to biologics [36].  
Within this chapter we will only face two of the most frequent and challenging EIM 
associated to paediatric IBD: 1) anaemia and 2) pancreatic involvement.   
 We will discuss these issues reporting the results of 2 different papers: “Serum 
Hepcidin and Iron Absorption in Pediatric Inflammatory Bowel Disease” published in 
Journal of Crohns and Colitis (J Crohns Colitis. 2016; 10:566-74) and “Natural history of 
pancreatic involvement in paediatric inflammatory bowel disease” published in 
Digestive and Liver Disease (Dig Liver Dis. 2015; 47:384-9).   
 
5.1 The role of hepcidin in IBD related anaemia 
 IBD related anaemia is probably the most frequent EIM both in children and adults, 
with a prevalence ranging from 15 to 75%, on the basis of the different reports [166-168].  
However, despite its relative high prevalence, costs and impact on patient’s quality of life, 
it is rarely considered and adequately treated [169, 170].  One of the main difficulties in IBD 
related anaemia is understanding which is the mechanism underneath.  Indeed, at least 3 
types of anaemia are identifiable during the management of patients with IBD: 1) iron 
deficiency anaemia (IDA), which represents the result of the chronic blood loss from the GI 
tract; 2) anaemia of inflammatory etiology, or anaemia of chronic disease (ACD), which is 
mainly the result of systemic inflammation, impairing both iron absorption and iron release 
into the blood; 3) combined IDA+ACD, determined in a variable measure by both the 
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reported mechanisms [171, 172].  Determining which type of anaemia may be important to 
better orientate the therapeutic management.  Indeed, in case of IDA, with negative 
inflammatory indexes, a cycle of oral iron may be recommended.  On the contrary, in case 
of clear ACD oral iron is strongly discouraged being completely useless and possibly 
harmful [173].  However, children with a mixed component represent the most challenging 
cases.  In those patients, it is often difficult to discriminate which is the prevalent 
mechanism with the traditional biomarkers (serum iron, ferritin, transferrin, CRP, etc.) and 
the clinician may face the dilemma whether or not to use oral iron [174].  
 The research of new possible biomarkers may certainly improve the management of 
IBD related anaemia.  Recent elucidations revealed hepcidin, as a possible candidate.  As 
well known, hepcidin is one of the most important iron regulator.  Its expression is, indeed, 
transcriptionally regulated in response to changing serum iron levels.  Elevated serum iron 
promotes hepcidin expression, leading to downregulation of ferroportin and decreased 
entry of iron into the circulation.  Conversely, low serum iron leads to reduced hepcidin 
expression, elevated ferroportin, and increased movement of iron into the circulation [175, 
176].  Hepcidin is thought to be the key markers in the pathogenesis of ACD.  Hence, in 
addition to iron status, inflammatory cytokines, such as interleukin 6, can also influence 
transcription of the hepcidin gene [177, 178].  Some papers tried to elucidate the role of 
hepcidin in the mechanisms of anaemia in pediatric IBD.  However, the results are limited 
and conflicting [179-183].  This may suggest that hepcidin in human IBD is likely to be 
influenced by various factors such as age, type of disease, and disease activity.   
 Given these premises, with the objective of clarifying some of these unanswered 
questions, we decided to conduct a prospective, observational study in our IBD cohort.  
The primary aim was to correlate hepcidin serum levels in IBD children with disease 
activity, inflammatory markers and iron absorption; the secondary aims were to compare 
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serum hepcidin levels of IBD patients with a group of celiac and healthy patients, and to 
establish which iron parameter better correlates with hepcidin.   
To realize these goals, we prospectively enrolled between December 2012 and June 2013 
50 IBD children, 45 celiac children and 50 healthy controls.  All the children underwent an 
extensive blood panel including the traditional iron markers and hepcidin measurement.  In 
addition, in order to evaluate the efficacy of iron absorption in IBD children, an iron load 
test (ILT) was performed.   
 The results of our study certainly brought new knowledge to this important topic.  
Indeed, this study represents the first, evaluating both iron absorption and serum hepcidin 
levels in IBD pediatric patients.  Our data showed that IBD children with active disease 
tend to have impaired iron absorption, driven through hepcidin pathway.  Indeed, serum 
hepcidin levels were significantly higher in IBD patients with moderate to severe activity as 
compared to all other groups, including patients with mild activity or in remission, celiac 
patients, and healthy controls.  In addition, a significant inverse correlation was found 
between hepcidin levels and iron absorption.  These findings are in agreement with the 
paper from Semrin and colleagues, the only paediatric study investigating the relationship 
between iron absorption and hepcidin, while the authors used urinary hepcidin as a proxy 
of serum hepcidin [179].   
 The prevalence of anaemia among IBD patients was 34% and, not surprisingly, the 
majority of the anaemic patients of our study population showed a combined IDA and ACD 
(70.5%).  Therefore, in most of our patients we could have been doubtful, whether or not to 
advise an oral iron cycle.  The treatment with oral iron has significant limitations in IBD, 
being certainly less efficacious than intravenous route [174].  In addition, absorption of iron 
from the GI tract is limited, and unabsorbed iron is exposed to the intestinal surface.  
Studies in animal models of colitis indicate that luminal iron may exacerbate disease 
activity [184, 185].  In a more recent study, iron supplementation affected microbiota and 
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increased faecal calprotectin [186].  Taking into account this possible warning, the recently 
published ECCO guidelines clearly state that intravenous route should be preferred in 
those patients with a suspicion of ACD [173].  On the other side, giving intravenous iron is 
not always feasible, both for high costs and patients’ compliance.  It is therefore important 
to screen the patients needing intravenous iron.  On the basis of our study, serum hepcidin 
may represent a useful surrogate marker to distinguish patients with impaired iron 
absorption.  With regards to the traditional markers, not surprisingly serum ferritin resulted 
to be the most strictly correlated to hepcidin [187].  However, 58.3% of patients, with a 
diagnosis of combined IDA+ACD and normal ferritin values, showed an increased 
hepcidin, demonstrating that ferritin is not sufficiently adequate in the differential diagnosis 
of IBD related anaemia.   
 In conclusion, our data clearly demonstrate that serum hepcidin is increased in IBD 
children with active disease and plays an important role in the process of iron 
malabsorption.  ACD is significantly prevalent in paediatric IBD and it should be taken in 
consideration before starting an oral iron therapy.  If confirmed by further studies, serum 
hepcidin may serve as a useful, sensitive, surrogate marker to distinguish patients with 
impaired iron absorption in whom intravenous iron could be used as first-line option, 
avoiding wasting time with a possibly harmful cycle of oral iron.   
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5.2 Pancreatic involvement in paediatric IBD 
 Pancreatic involvement (PI) in patients with IBD includes all the spectrum of clinical 
presentations from asymptomatic hyper-enzinemia to chronic pancreatitis (CP) with 
development of pancreatic insufficiency [188].  Although this EIM seems to be much more 
frequently observed than reported, data about the prevalence and the incidence of PI in 
IBD are not well defined both in adults and children.  The incidence of PI varies widely in 
IBD adult patients, ranging from 5% to 21% [189, 190].  According to several studies, 
hyperamylasemia (HA) and exocrine pancreatic insufficiency are found in 6–16 and 21–
80% of adult patients, respectively, whereas histological changes are observed in 38–53% 
of post-mortem pathological examinations [189-192].  With regards to IBD paediatric patients 
there are only limited published data on the incidence of acute pancreatitis (AP) [193, 194].   
There are many possible etiological factors, which link IBD and PI [195]:  
• Drugs assumption;  
• Biliary lithiasis, which is known to be more frequent in IBD; 
• CD duodenal involvement; 
• Sclerosing cholangitis. 
Furthermore, it is worth citing, the rare variant of autoimmune pancreatitis, which has been 
described to occur more frequently among IBD patients [196].  With regards to drugs, 
several case reports about drug-induced pancreatitis have been published [197].  Although it 
is always difficult to establish a causal role for medications, few drugs are clearly 
associated with a high risk for drug-induced pancreatitis.  The medications used for the 
IBD management, associated with the PI development, are 5-ASA compounds, AZA, 
metronidazole and CCS [195, 198].  Nevertheless, besides these well-known etiological 
factors, it appears that IBD itself may contribute to the pathogenesis of PI [188].   
As above-mentioned, in addition to the more classical clinical manifestations of PI, children 
with IBD may often present an asymptomatic hyper-amylasemia (HA) and hyper-lipasemia 
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(HL), which may be completely misdiagnosed.  Various possible explanations for 
asymptomatic HA and HL in IBD patients have been proposed.  The pancreatic enzyme 
elevation observed in more extensive or active disease can represent the abnormal 
passage of the enzyme from the gut lumen to the blood, due to the increased permeability 
of the inflamed mucosa [199].  In addition, there are several potential mechanisms for the 
suggested enzyme leakage from the pancreas.  First, the pancreas might be affected in 
some way directly by the extent of IBD.  Another explanation could be an enzyme increase 
related to the pancreatic effects of inflammatory mediators and cytokines released from 
the inflamed gut.  A third mechanism might be associated with inflammation of pancreatic 
ducts [189].  With regards to outcomes of PI and treatment, few limited data are available.   
As well known, there is no specific therapy for PI.  Therefore, the supportive treatment, 
including fasting, rehydration, proton pump inhibitor and antibiotic therapies, is also used in 
PI associated to IBD [195].   
 Despite limited reports, the relationship between PI and IBD has not been further 
investigated, particularly in paediatrics.  For these reason, we conducted a retrospective 
study, using the IBD web-registry of the Italian Society for Paediatric Gastroenterology and 
Nutrition (SIGENP) to address the following objectives: 
1. To investigate prevalence and disease course of IBD paediatric patients presenting 
with pancreatitis;  
2. To evaluate the clinical significance of exclusive HA and HL in IBD children.   
 
From 2009 to 2012 649 patients with a diagnosis of IBD were identified, of whom 27 
(4.1%) resulted to be affected by PI.  Among patients diagnosed with PI, 11 (1.6%) fulfilled 
diagnostic criteria for AP, while the remaining 16 showed only an asymptomatic HA and 
HL.  One interesting finding is that up to 18% of AP cases was already present at IBD 
onset.  Broide and colleagues reported that AP may even precede the diagnosis of IBD 
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[193].  These data may suggest that at least in a subset of patients the intestinal and the 
pancreatic inflammation may be part of the same autoimmune disorder.  As a matter of 
fact, 81.2% of patients with hyperenzinemia and 90.8% of children with AP showed an 
active intestinal disease.  One of the hypotheses is that the epithelial cells of the GI tract 
and the pancreatic tissue may share similar target molecular or cellular structures 
vulnerable to injury.  This thesis is also supported by a mouse model [200].  In 2005, Barthet 
and colleagues reported that mice affected by trinitrobenzene sulfonic acid-induced colitis, 
showed concurrently to intestinal lesions, specific pancreatic lesions.  The authors 
concluded that in some cases PI and IBD may be different manifestations of the same 
disease [200].  We tried also to find out if there was any risk factor, allowing discriminating 
children with simple asymptomatic hyperenzinemia from patients developing an actual AP.   
The only significant factor resulted female gender.  Bermejo et al. have already reported 
this finding in an adult population looking at the risk of AP in patients undergoing AZA 
treatment [201].  In addition, it looked like that patients with PI tend to have a major colonic 
involvement.  The association between colonic disease and PI remains obscure.  One 
possible explanation may be that the colon is considered a major source of the bacteria 
causing pancreatic necrosis in AP.  Supporting this hypothesis subtotal colectomy before 
AP in rats was found to reduce mortality [202].   
 The results of our study give also important information regarding the clinical 
management of PI in IBD children.  As well known, nausea and vomiting with abdominal 
pain are the most usual features associated with a diagnosis of acute or chronic 
pancreatitis.  In IBD children, these symptoms need to be considered non-specific, since 
they may easily overlap with IBD flares.  Indeed, abdominal pain during an episode of 
pancreatitis may be falsely attributed to active IBD and serum levels of amylase or lipase 
never tested resulting in an underestimation of AP incidence [195].  Our data confirmed that 
symptoms were not able to discriminate patients with exclusive increase of pancreatic 
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enzymes from patients with AP, suggesting that pancreatic imaging should be routinely 
evaluated in all IBD patients with a PI suspicion.   
 Another important issue is those related to the medications.  As already mentioned, 
AZA e 5-ASA may be responsible of PI in children with IBD, although it is always difficult to 
establish a clean causal relationship [203-205].  Our study did not provide insights regarding 
this topic, but it gives an idea of the real practice in Italian centres.  Indeed, we 
demonstrated that among children needing therapeutic measures, 85% of subjects 
withdrew AZA and/or suspended 5-ASA.  This confirms that although the supportive 
literature is poor, clinicians tend to be very prudent in the management of these 
medications in the presence of PI.   
 Finally, our study is the first reporting data regarding the natural history of disease in 
IBD children with PI.  Although in all our cases the severity of AP episodes was mild and 
self-limiting, some of them tend to recur during the follow up.  Furthermore, at one-year 
follow-up, 1 patient showed a rapid evolution toward CP and consequent pancreatic 
insufficiency, suggesting that, in a subgroup of IBD patients, pancreatic dysfunction may 
not have a favourable course.  Although the clinical significance of exclusive HA/HL has 
been questioned, the disease course of our patients seems not to be always benign.  In 
our cohort, at 6 months follow-up, 25% of children with exclusive increase of pancreatic 
enzymes at the enrolment developed AP and at 12 months follow-up, 32.3% had 
persistent HA/HL.   
 In conclusion, the prevalence of AP in children is similar to that reported in adults.  
Our data support the thesis that in at least a subset of patients, IBD and PI may be part of 
the same systemic disorder.  PI is more common in colonic disease and female gender 
seems to be significantly associated with the development of AP in IBD children.  This 
study underlines that specific attention has to be paid to the monitoring of pancreatic 
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function in IBD children, considering that in a proportion of patients, PI tends to persist and 
in some cases the pancreatic damage may evolve.   
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CHAPTER 6 
 
IMPROVING THERAPEUTIC STRATEGIES  
 As widely discussed within Chapter 1, the therapeutic approach has profoundly 
evolving in the last decades with a growing trend to use a more aggressive “top-down” 
approach in order to reach and maintain a stable remission, and above all to modify the 
natural history of disease and reduce complications.  In line with this topic within this 
chapter we will revise the SIGENP multicentre paper “Effect of Early Versus Late 
Azathioprine Therapy in Pediatric Ulcerative Colitis” published in Inflammatory Bowel 
Disease (Inflamm Bowel Dis. 2016; 22:1647-54).  This paper was an attempt to verify if the 
early introduction of AZA in paediatric UC may positively change the course of disease.   
Finally, we will also discuss the results of the paper “Pediatric ulcerative colitis surgery: 
Italian survey” published in Journal of Crohn’s and colitis (J Crohns Colitis. 2015; 9:558-
64).  This paper describes the role and the outcomes of surgery in UC.  Indeed, despite 
the great medical armamentarium, surgery keeps still its own role in the therapeutic 
management of UC, as possible curative means after the drugs’ failure.  Understanding 
the exact timing to send our children to the surgeon is often crucial for their prognosis.  
  
6.1 Role of early immunosuppression in UC 
 As well underlined in chapter 1 and 3, paediatric UC is characterized by a more 
severe disease course when compared to adults [8, 115, 131].  Nevertheless, current 
guidelines still do not recommend any kind of top-down approach.  At the same time, an 
accelerated step-up approach using AZA from the diagnosis is only suggested in ASC [50].  
Although, it is now well known that the conventional “step-up” approach does not impact 
on the risk of surgery overtime, there is a lack of evidences and RCTs on the efficacy of a 
more aggressive approach starting from the diagnosis.  In addition, risk stratification of UC 
children has been poorly defined.  To date only early onset disease, female gender, 
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extensive colitis at diagnosis, and a systemic CCS therapy at disease presentation have 
been identified as possible predictors of worst disease outcomes [206-208].  As a matter of 
fact, the role of early immunosuppression in paediatric UC has not been deeply 
investigated.  The idea that starting immunosuppressive drugs, and in particularly 
thiopurines, early from the diagnosis, with the so-called accelerated “step-up” approach, 
may ameliorate the long-term outcomes of the disease, comes from studies on paediatric 
CD.  The first data were published by Markowitz et al. early in 2000 [209].  The authors 
conducted a RCT, enrolling 55 children with newly diagnosed moderate-to-severe CD who 
were randomized to receive an initial course of prednisone and either 6-mercaptopurine 
(6-MP) or placebo and were followed-up till 18 months [209].  Patients taking 6-MP had a 
reduced total duration of corticosteroid usage, and their cumulative steroid dose received 
was also less when compared to the placebo group.  Astonishingly only 9% of the 6-MP 
group relapsed during the study period compared with 47% of the controls [209].  However, 
this study had several limitations, including the fact that it was not sufficiently powered.  
Following studies, although not replicating the same efficacy, were anyway able to 
demonstrate the efficacy of early AZA introduction at least as a steroid-spare agent [210, 
211].   Therefore, an “accelerated” step-up approach, based on the initiation of thiopurines, 
became commonly used in clinical practice for the treatment of CD.  Translating data from 
CD, many centres started to do the same in children affected by severe UC.   
Nevertheless, data on the short- and long-term efficacy of an accelerated step-up strategy 
in UC	 is lacking and studies are strongly needed in order to define new efficacious 
therapeutic strategies in paediatric UC.   
 Therefore, we conducted a retrospective analysis of the IBD web-registry of the 
Italian Society for Paediatric Gastroenterology and Nutrition (SIGENP) and collected the 
data of all children with UC treated with AZA within 24 months of diagnosis, from January 
1, 2009, to January 5, 2015.  The primary aim of this analysis was to describe the efficacy 
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of AZA in newly diagnosed paediatric UC, comparing the outcomes of early (0-6 months of 
diagnosis) versus late (6-24 months) initiation of therapy.   
 One-hundred-twenty-one children were included in the analysis.  Seventy-six 
patients (63%) were treated with AZA within 6 months of diagnosis ("early" group), 45 
(37%) between 6–24 months after diagnosis ("late" group).   
 The results of this study evaluating the impact of the timing of initiation of AZA on 
sustainable clinical remission and mucosal healing in paediatric UC, failed to demonstrate 
the superiority of early treatment compared to classical step-up approach.  Moreover, our 
data suggest that an accelerated use of thiopurines has no steroid-sparing effect 
compared to conventional treatment, since no difference in CCS use was found between 
groups at any time point of follow-up. 	No significant differences were also noticed with 
regards to colectomy.  Indeed, at 2 years of follow-up the rate of surgery was comparable 
between early and late group.  	
	 To our knowledge, no other reports on the effect of early immunomodulatory 
therapy in paediatric UC have been published so far.		Only recently two population-based 
studies on the impact of thiopurines questioned their early use, reporting no efficacy in 
reducing the risk of colectomy in adults and adolescents with UC [212, 213].   
	 Regarding MH, we found an overall rate of 37% and 40% at 1- and 2-year follow-
up, respectively.  These results are similar to those reported in literature [214, 215].  When 
comparing MH in early and late patients we didn’t find any difference for MH rates both at 
12 and 24 months, suggesting that the timing of AZA introduction has no impact on the 
ability of AZA to heal the intestinal mucosa in paediatric UC.  Also, when evaluating other 
secondary outcomes, including the number of hospitalizations, need of treatment 
escalation and episodes of ASC, no difference was found based on the timing of AZA 
initiation.   
 As said, thiopurines have their own established role as maintenance therapy in both 
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adult and paediatric UC.  However, taken together, our results strongly discourage their 
use as an early-step-up accelerated treatment in UC.  Nevertheless, it has to be 
underlined that our study had several limitations, including the retrospective nature and the 
enrolment within the early treatment group of many patients starting AZA 6 months after 
the diagnosis.  Indeed, starting AZA at the onset of disease, contemporarily with the 
initiation of CCS, may have different outcomes.  Therefore, well-designed randomized 
controlled trials are needed to confirm or not our findings and to select those patients who 
may benefit from an early immunosuppressive therapy.   
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6.3 Role and outcomes of surgery in UC 
 The progresses of medical therapy and the increase of options for second-line 
treatment of UC children have significantly reduced the need for colectomy.  As reported in 
chapter 3, this is clearly demonstrated by the decrease of surgery rate from 1990s [216].   
 On the basis of the last updated ESPGHAN guidelines on the management of 
paediatric UC, an elective colectomy may be indicated in children with active or steroid-
dependent UC despite maximal treatment with 5-ASA, thiopurines, and anti-TNF therapy, 
or after the finding of colonic dysplasia [EL5, RG D; adults EL 4, RG C] [50].  Indeed, 
differently from adults, in whom the main indication to colectomy is represented by 
dysplasia, children are usually referred to the surgeon for a chronic on-going steroid-
dependent disease [50].  In general, most of the paediatric gastroenterologists tries to 
implement immunomodulatory agents and biologics therapy to their more effective doses 
before referral to colectomy.  However, as suggested by the low level of evidence of the 
ESPGHAN recommendation, differently from medical therapy much less have been 
reported on surgical treatment needs of UC children.  Several studies tried to identify 
factors associated with progression to colectomy, but there is still no general agreement 
on the surgical indication, timing and techniques [217-220].  The timing is a particularly hot 
topic in paediatrics, considering that children with active UC are at high risk of delayed 
growth and puberty.  An appropriate, prompt surgical intervention may be able to restore 
growth and improve quality of the life [221].   
 With regards to the preferred technique, the literature is much more conclusive and 
there is a quite widespread agreement.  Restorative proctocolectomy (ileoanal pouch or 
ileal pouch-anal anastomosis), especially the J-pouch, should be certainly preferred over 
straight pull-through (ileoanal) or ileorectal anastomosis for elective surgery of paediatric 
UC.  Most series reported better continence after the pouch procedure [221-223].  In 
particular, a paediatric meta-analysis consisting of 5 studies and 306 patients suggested 
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that the straight ileoanal pull-through was associated with a higher failure risk (15% for 
straight pull through vs 8% for pouch procedure), and perianal sepsis (20% vs 10%), as 
well as a higher stool frequency [223].  Because the quality of life in children with restorative 
proctocolectomy is inversely related to stool frequency and continence, this difference is 
clinically relevant [221].  However, the pouch procedure is associated with risk for pouchitis 
[223].  Finally, considering the low complications rates and better cosmetics effects, when 
possible, laparoscopic approach is usually preferred [50].   
 In order to characterize the practice in terms of surgery of UC children among 7 
Italian referral centres for paediatric gastroenterology, we performed a retrospective study, 
collecting all cases of UC surgery from 2009 to 2013.  The aims of the survey were to 
define the surgical management of paediatric patients affected with UC, focusing on 
details of surgical technique, postoperative complications and quality of life, and to 
describe and compare attitudes among paediatric surgeons.   
 Our study represents the first Italian survey of UC children, focused on the surgical 
management of this population.  After evaluating the attitude of each referring centre, we 
found a general consensus regarding indications for surgery, in accordance with the 
guidelines proposed by the ESPGHAN [50].  As previously reported, in our series the main 
indication for colectomy was failure of medical therapy (56%), followed by ASC (34%) and 
side effects of medical therapy (9.8%).   
 With regards to the timing of surgery, as underlined, there is still no consensus 
among paediatric gastroenterologists and surgeons.  Although few paediatric data have 
been published, some papers suggested that delayed surgery may be associated with an 
increased risk of complications [224].  In this study colectomy was performed at a median 
interval of 2.5 years after diagnosis.  One of the most intriguing finding is that up to 40% of 
the cases performed surgery after 1 month from the diagnosis, once more underlining the 
severity of certain subtypes of paediatric UC.  This high percentage of early surgery may 
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explain also the low rate of complications, in according with the previous literature [221-223].  
Concerning the technique, most of the participating centres correctly performed restorative 
proctocolectomy with ileal J-pouch–anal anastomosis.  In addition, centres using a straight 
anastomosis at the beginning of this study progressively moved towards pouch surgery, 
demonstrating the adherence to the guidelines [50].  Nevertheless, the study still underlined 
many differences in terms of laparoscopic approach.  As a matter of fact, its use in 
reconstructive surgery remains limited to a few centres because of the technical skills 
required at this stage.  Centralization of specialized centres should be considered in order 
to provide these patients with the benefits of a laparoscopic approach.   
 Finally, we confirmed that proctorestorative colectomy is superior to the straight 
anastomosis both in terms of continence and stool frequency.  Indeed, at 1 year of follow-
up, children belonging to the straight anastomosis group showed a higher frequency of 
daytime and night-time incontinence than the pouch group, and a higher stool frequency 
with more than 10 daily evacuations.  Probably due to the small follow-up (12 months after 
surgery) data from our series showed a lower rate of pouch inflammation.   
 In conclusion, this study demonstrated a general agreement to the ESPGHAN 
guidelines in terms of indications and technique.  Restorative proctocolectomy with ileal J-
pouch–anal anastomosis resulted the intervention of choice and once more demonstrated 
its superiority in terms of continence and stool frequency with a low rate of complications.  
Further follow-up is needed to define the long-term quality of life and pouchitis risk in our 
population.  Larger studies are needed to define the optimum timing for surgery.   
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CHAPTER 7 
CONCLUSIVE REMARKS 
 This thesis project clearly outlines the burden, the unique features and the complex 
management of paediatric IBD.  The medical advances made in the last 20 years have 
certainly optimized the ability to care for these patients, allowing the reach of objectives 
and goals not imaginable before.  The IBD management by paediatric gastroenterologists 
is progressively moving from symptomatic control to achievement of mucosal healing and 
deep remission with the use of more targeted agents.  This is due to a growing awareness 
that early use of disease-modifying drugs can alter the natural history and limit disease 
progression.  As a matter of fact, thanks to the technological progresses, we made further 
steps in the comprehension of genetics and microbiome, allowing a better understanding 
of IBD pathogenetic mechanisms.  This consented the development of more targeted 
molecules able to counteract specific pathways along the disease inflammatory cascade.  
These new drugs are slowly coming out and will be soon available also in paediatric age.  
The increasing therapeutic armamentarium will hopefully lead to more patient-tailored 
treatment approaches.   
 Nevertheless, there are still many gaps that research need to address soon.  
Probably, as previously underlined, the most pressing issue in the management of 
paediatric IBD is the improvement of patients’ risk stratification.  Indeed, we are still far 
from the expected and advocated personalized approach.  This implies a further 
improvement in the understanding and the classification of genetic background, serological 
markers, endoscopic and imaging features.   
 On the other hand, the impressive data on the continuous increase of disease 
incidence, as well as the new reports from less developed countries, highlight the need for 
developing preventive strategies.  To make this objective achievable a further effort is 
needed to better clarify the influence and the interaction of the exposome with microbiome 
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and genetics.  This last step will allow us to establish preventive strategies and face the 
current IBD epidemic.   
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CHAPTER 9 
CURRICULUM VITAE 
Main Research Fields: 
1) Clinical and therapeutic management of children affected by IBD; 
2) Characterization of paediatric IBD pathogenesis; 
3) Endoscopic assessment of children affected by IBD, intestinal polyposis, 
gastroesophageal reflux disease and celiac disease; 
4) Clinical and therapeutic management of Functional Gastrointestinal Disorders in 
children; 
5) Clinical and therapeutic management of gastrointestinal disorders among children with 
neurological disabilities. 
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Grants and Awards 
• ESPGHAN Young Investigator Award for the communication “Intestinal Iron 
Absorption in Pediatric Inflammatory Bowel Disease: a Prospective, Single-Center”, 
presented at the ESPGHAN 47th Annual Meeting, June 9-12 2014, Jerusalem, 
Israel.  
 
Invited as a speaker  
• Clinical Case Based Discussion. Joint Meeting IG-IBD-SIGENP. La gestione della 
terapia con farmaci biologici nel bambino con Malattia Infiammatoria Cronica 
Intestinale. Palermo, 3 Dicembre, 2015.  
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• Problematiche gastroenterologiche tra funzionale ed organico: La Stipsi. Corso di 
formazione in Gastroenterologia ed Epatologia Pediatrica. Manfredonia (FG), 12 
Dicembre, 2015.  
• Novità in Nutrizione Pediatrica: Malattie Infiammatorie Croniche Intestinali. 
Workshop Avanzato di Nutrizione Neonatale e Pediatrica. Cagliari, 30 Giugno, 
2016.  
• Le Videocapsula Endoscopica in pazienti pediatrici. Incontro RAVE: 1° Riunione 
Annuale Videocapsula Endoscopica. Villa Braida-Migliano Veneto, 16-17 Settembre 
2016. 
• La rettorragia: I quesiti del clinico.  Pediatria a Napoli: il quesito del clinic e la 
soluzione multidisciplinare, Napoli, 26-28 Gennaio 2017. 
 
Teaching Activities 
• Professor of the Postgraduate Course in Paediatric Gastroenterology, Hepatology 
and Nutrition held at the Department of Paediatrics of the University of Naples 
“Federico II”, edition 2014, 2015 and 2016.  
